Bold shift in cancer treatment: Gilead will acquire Arcellx for up to $7.8 billion, expanding their joint cell therapy efforts that began in 2022.
A Gilead Sciences office image from Foster City, California, is included in the backdrop of the announcement.
Gilead said on Monday that it will purchase Arcellx, valuing the deal at an implied equity value of $7.8 billion. The takeover would extend the long-running collaboration between the two companies on cell therapies that started in 2022.
As news broke, Arcellx’s stock jumped 77.8%, rising to $113.99, while Gilead’s shares slipped roughly 1% in premarket trading.
The total consideration is $115 per Arcellx share in cash at closing, representing a premium of 79% to the stock’s previous close.
Historically, Kite Pharma, a Gilead unit, partnered with Arcellx to jointly develop and commercialize anito-cel, an experimental CAR-T therapy aimed at multiple myeloma, a form of blood cancer.
CAR-T cell therapy is a treatment that uses a patient’s own genetically modified immune cells to target and destroy cancer cells.
The U.S. Food and Drug Administration (FDA) is currently evaluating anito-cel, with a decision anticipated by December 23 of this year.
If the FDA approves anito-cel, the proposed acquisition is expected to be earnings-per-share (EPS) accretive for Gilead starting in 2028 and continuing thereafter.
Additionally, Gilead will pay Arcellx shareholders $5 per share, contingent on the achievement of cumulative global net sales of anito-cel totaling at least $6 billion from launch through the end of 2029.
But here’s where it gets controversial: the timing of the FDA decision and the substantial premium raise questions about price versus potential long-term value. And this is the part most people miss—the deal aligns a major traditional pharma player with a cutting-edge cell therapy, potentially accelerating patient access while raising concerns about integration risk and how soon the anticipated sales milestones might translate into real returns.
What this means for patients, investors, and competitors is complex and worth watching closely as the regulatory review unfolds and the integration progresses.
